go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Bayer Limited

Bayer Limited
The Atrium, Blackthorn Road, Dublin 18,
Telephone: +353 1 2999 313
Fax: +353 1 2061 456


Summary of Product Characteristics last updated on medicines.ie: 22/08/2011
SPC Redoxon Double Action Effervescent Tablets

Table of Contents

  • 1. NAME OF THE MEDICINAL PRODUCT
  • 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
  • 3. PHARMACEUTICAL FORM
  • 4. CLINICAL PARTICULARS
  • 4.1 Therapeutic indications
  • 4.2 Posology and method of administration
  • 4.3 Contraindications
  • 4.4 Special warnings and precautions for use
  • 4.5 Interaction with other medicinal products and other forms of interaction
  • 4.6 Pregnancy and lactation
  • 4.7 Effects on ability to drive and use machines
  • 4.8 Undesirable effects
  • 4.9 Overdose
  • 5. PHARMACOLOGICAL PROPERTIES
  • 5.1 Pharmacodynamic properties
  • 5.2 Pharmacokinetic properties
  • 5.3 Preclinical safety data
  • 6. PHARMACEUTICAL PARTICULARS
  • 6.1 List of excipients
  • 6.2 Incompatibilities
  • 6.3 Shelf life
  • 6.4 Special precautions for storage
  • 6.5 Nature and contents of container
  • 6.6 Special precautions for disposal and other handling
  • 7. MARKETING AUTHORISATION HOLDER
  • 8. MARKETING AUTHORISATION NUMBER(S)
  • 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
  • 10. DATE OF REVISION OF THE TEXT


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Redoxon Double Action 1000mg/10mg Effervescent Tablets


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

1 effervescent tablet contains:

Ascorbic acid (vitamin C)

1000 mg

Zinc (in form of 32 mg zinc citrate trihydrate)

10 mg

Excipients:

Aspartame

15mg

Sorbitol

655mg

Sodium

8.4mmol

For a full list of excipients, see section 6.1


Go to top of the page
3. PHARMACEUTICAL FORM

Effervescent Tablet.

Light orange round tablet with bevelled edges and flat faces with a smell of orange.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Treatment of ascorbic acid and zinc deficiency.


Go to top of the page
4.2 Posology and method of administration

Adults and children over 12 years: 1 effervescent tablet a day dissolved in a glass of water.


Go to top of the page
4.3 Contraindications

In nephrolithiasis accompanied by oxaluria with aciduria or normal urinary pH, vitamin C should not be given if the dose of vitamin C is > 1g/day.

REDOXON DOUBLE ACTION must not be taken by persons known to be hypersensitive to any of its ingredients.


Go to top of the page
4.4 Special warnings and precautions for use

REDOXON Double Action contains a source of phenylalanine and, therefore, may be harmful to people with phenylketonuria.

Patients suffering from renal insufficiency should consult a physician prior to intake of large doses of ascorbic acid.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

At high doses (more than 2 g/day) vitamin C may interfere with the following biological tests: plasmatic and urinary dosages of creatinine and glucose (control with glucose-oxydase device) as well as with tests for occult bleeding in stool.


Go to top of the page
4.6 Pregnancy and lactation

No teratogenicity study in animals is available.

Clinical observations of a great number of exposed pregnant women have not shown any malformative or toxic effect of REDOXON Double Action on the fœtus. However, only epidemiological studies could check the absence of any risk.

Consequently, REDOXON Double Action should only be used during pregnancy if necessary.

The vitamin and mineral of REDOXON Double Action effervescent tablets are excreted in the milk, but harmful effect on the child are unlikely at the therapeutic doses.


Go to top of the page
4.7 Effects on ability to drive and use machines

None.


Go to top of the page
4.8 Undesirable effects

The most commonly found adverse reactions are mild transient multivitamin/mineral gastrointestinal disturbances (>=1/100 - <1/10).

Allergic reactions are very rare (<1/10,000). Urticaria, throat swelling and rash have been reported in isolate cases.

Ascorbic acid may cause haemolytic anaemia in certain individuals with a deficiency of glucose-6-phosphate dehydrogenase.


Go to top of the page
4.9 Overdose

No cases of overdose are known.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

ATC Code: A11GB

Vitamin C

Ascorbic acid is an important water-soluble vitamin and antioxidant. Due to the low storage capacity of the body for vitamin C, a regular intake of sufficient amounts is essential to humans.

Ascorbic acid and its metabolite dehydroascorbic acid form a reversible redox system that is involved in many enzymatic reactions and forms the basis for the spectrum of action of vitamin C. Ascorbic acid functions as a cofactor in a number of hydroxylation and amidation reactions by transferring electrons to enzymes that provide reducing equivalents.

The importance of ascorbic acid to the human body is most clearly evident in clinically manifest vitamin C deficiency, i.e. scurvy. Ascorbic acid plays a key role in the production of hydroxyproline from proline, which in turn is essential to the development of functionally active collagen. The symptoms seen in scurvy, such as delayed wound healing, disturbances of bone growth, vascular fragility, and disorders of dentine formation, are the result of impaired collagen formation.

Zinc

As with vitamin C, low levels of zinc may also adversely affect the healing rate of wounds, ulcers and decubitus.

Zinc status is of major importance in maintenance of effective immune response, particularly T-cell-mediated response.


Go to top of the page
5.2 Pharmacokinetic properties

Absorption: Ascorbic acid is absorbed primarily in the upper part of the small intestine via sodium-dependent active transport. When ascorbic acid is present in high concentrations, uptake occurs by means of passive diffusion. After oral administration of doses of 1-12 g, the proportion of ascorbic acid absorbed falls from approximately 50% to about 15%, though the absolute quantity of substance taken up continues to increase.

Zinc is absorbed all along the small intestine. The absorption of zinc (ionic) administered in solution on an empty stomach ranges from 41-79%, while the zinc present in foods or that given as a supplement with meals is absorbed in the range of 10–40%.

Distribution: Plasma protein binding of ascorbic acid is approximately 24%. Serum concentrations are normally 10 mg/l (60 µmol/l). Concentrations below 6 mg/l (35 µmol/l) indicate that the intake of vitamin C is not always adequate, and concentrations below 4 mg/l (20 µmol/l) indicate that the intake is actually inadequate. In clinically manifest scurvy, serum concentrations are below 2 mg/l (10 µmol/l).

Total body zinc content is controlled in part by regulating the efficiency of intestinal absorption and the excretion from endogenous zinc pools to maintain zinc homeostasis. The adult total body zinc content ranges from about 2.3 mmol (1.5 g) in women to 3.8 mmol (2.5 g) in men. Zinc is present in all organs, tissues, fluids, and secretions of the body. Zinc is primarily an intracellular ion, with well over 95% of the total-body zinc found within cells. Zinc is associated with all organelles of the cell, but about 60 to 80% of the cellular zinc is found in the cytosol.

Metabolism: Ascorbic acid is metabolised partly via dehydroascorbic acid to oxalic acid and other products. When ingested in excessive quantities, however, ascorbic acid is largely excreted in unchanged form in the urine and faeces. Ascorbic-acid-2-sulphate also appears as a metabolite in the urine.

Elimination: The physiological body pool of ascorbic acid is about 1500 mg. The elimination half-life of ascorbic acid depends on the route of administration, the quantity administered and the rate of absorption. Following an oral dose of 1 g the half-life is about 13 hours. When 1-3 g vitamin C /day is taken, the main route of excretion is renal. With doses exceeding 3 g, increasing quantities are excreted unchanged in the faeces.

The major route for endogenous zinc excretion is into the gastrointestinal tract with ultimate loss in the faeces. When tracer doses of zinc are given either orally or intravenously, only about 2 to 10% is recovered in the urine; the remainder is lost in the faeces. In humans, endogenous faecal losses may range from <15 μmol/day (1 mg/day) with extremely low intakes to over 80 μmol/day (5 mg/day) with extremely high intakes. Normally, about 6 to 9 μmol (400 to 600 μg) of zinc is excreted daily in the urine.


Go to top of the page
5.3 Preclinical safety data

Not applicable.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Sodium hydrogen carbonate

Anhydrous sodium carbonate

Anhydrous citric acid

Sorbitol (E420)

Aspartame (E951)

Acesulfame potassium

Sodium chloride

Orange flavour (acetaldehyde, ascorbic acid, ethyl butyrate, decanal, dodecanal, hexanal, orange oil, linalol, tetradecanal, nonalal, octanal, acacia and maltodextrin)

Tangerine flavour (ascorbic acid, tangerine oil, acacia and maltodextrin) beta-carotene 1% (beta carotene crystalline, alpha tocopherol, sodium ascorbate crystalline, medium chain triglycerides, acacia, sucrose, maltodextrin and silicon dioxide)


Go to top of the page
6.2 Incompatibilities

Not applicable.


Go to top of the page
6.3 Shelf life

3 years in plastic tubes or aluminium tubes.

2 years in aluminium foil strip.


Go to top of the page
6.4 Special precautions for storage

Store below 25 °C.

Keep the tube tightly closed, in order to protect from moisture.


Go to top of the page
6.5 Nature and contents of container

10, 15, 20 or 30 tablets in aluminium tube with polyester lacquer closed by a PE stopper containing a desiccant (silica gel) or in polypropylene tube closed by a PE stopper containing a desiccant (silica gel)

Box of 1 or 2 tubes containing 10 or 15 tablets

1 tablet in aluminium / PE strip

Not all pack sizes may be marketed.


Go to top of the page
6.6 Special precautions for disposal and other handling

No special requirements.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

BayerLtd

The Atrium

Blackthorn Road

Dublin 18


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PA 1410/50/1


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 2nd November 2001

Date of last authorisation: 1st April 2009


Go to top of the page
10. DATE OF REVISION OF THE TEXT

May 2011



Link to this document from your website:
http://www.medicines.ie/medicine/10271/SPC/Redoxon+Double+Action+Effervescent+Tablets/

Document Links

 
  Link to this page
  View all medicines
from this company
Print this page
View document history
Bookmark and Share

Legal Categories

 
   Product subject to medical
prescription which may not
be renewed (A)
   Product subject to medical
prescription which may
be renewed (B)
   Product subject to
restricted prescription
(C)
   Supply through
general sale
   Supply through
pharmacy only

Active Ingredients

 
   Ascorbic Acid (Vitamin C)
   Zinc citrate trihydrate

  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo